Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
The return on equity (ROE) is N/A as of the fiscal period ended Friday, September 30, 2022.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q3 FY2022 (2022-09-30): -448.71%.
RETURN ON EQUITY (ROE)
N/A
RETURN ON EQUITY (ROE) AVG TTM
-208.64%
RETURN ON EQUITY (ROE) AVG 3Y
N/A
RETURN ON EQUITY (ROE) AVG 5Y
N/A
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Foghorn Therapeutics Inc.
Market Cap
$117.43M
Return on Equity (ROE)
N/A
TTM Avg
-208.64%
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$118.02M
Return on Equity (ROE)
-105.40%
TTM Avg
-90.09%
3Y Avg
-60.23%
5Y Avg
-18.64%
Market Cap
$116.59M
Return on Equity (ROE)
-209.73%
TTM Avg
-196.07%
3Y Avg
-130.72%
5Y Avg
-67.26%
Market Cap
$118.50M
Return on Equity (ROE)
N/A
TTM Avg
326.93%
3Y Avg
83.50%
5Y Avg
24.39%
Market Cap
$118.63M
Return on Equity (ROE)
-5.10%
TTM Avg
-4.24%
3Y Avg
-6.16%
5Y Avg
0.09%
Market Cap
$119.09M
Return on Equity (ROE)
-165.57%
TTM Avg
-146.09%
3Y Avg
30.63%
5Y Avg
465.14%
Market Cap
$114.24M
Return on Equity (ROE)
-93.44%
TTM Avg
-8.16%
3Y Avg
13.24%
5Y Avg
13.24%
Market Cap
$113.77M
Return on Equity (ROE)
-0.05%
TTM Avg
-43.47%
3Y Avg
9.13%
5Y Avg
-18.50%
Market Cap
$111.17M
Return on Equity (ROE)
-44.29%
TTM Avg
-31.86%
3Y Avg
-53.29%
5Y Avg
-49.85%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Foghorn Therapeutics Inc. (FHTX) | $117.43M | N/A | -208.64% | N/A | N/A |
| Caribou Biosciences, Inc. (CRBU)vs › | $118.02M | -105.40% | -90.09% | -60.23% | -18.64% |
| Genelux Corporation (GNLX)vs › | $116.59M | -209.73% | -196.07% | -130.72% | -67.26% |
| Insight Molecular Diagnostics Inc. (IMDX)vs › | $118.50M | N/A | 326.93% | 83.50% | 24.39% |
| BGM Group Ltd. (BGM)vs › | $118.63M | -5.10% | -4.24% | -6.16% | 0.09% |
| TuHURA Biosciences, Inc. (HURA)vs › | $119.09M | -165.57% | -146.09% | 30.63% | 465.14% |
| Aardvark Therapeutics, Inc. Common Stock (AARD)vs › | $114.24M | -93.44% | -8.16% | 13.24% | 13.24% |
| Coya Therapeutics, Inc. (COYA)vs › | $113.77M | -0.05% | -43.47% | 9.13% | -18.50% |
| Black Diamond Therapeutics, Inc. (BDTX)vs › | $111.17M | -44.29% | -31.86% | -53.29% | -49.85% |
| Immunic, Inc. (IMUX)vs › | $109.93M | -87.45% | 455.42% | 120.34% | 63.42% |
ROE
N/A
ROA
-31.8%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2022-09-30 | -448.71% |
| 2022-06-30 | -229.78% |
| 2022-03-31 | -145.37% |
| 2021-12-31 | -104.59% |
| 2021-09-30 | -114.76% |
| 2021-06-30 | -81.79% |
| 2021-03-31 | -62.19% |
| 2020-12-31 | -47.06% |
| 2020-06-30 | -320.54% |
